Literature DB >> 22766031

Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study.

Nicola J Ray1, Janis M Miyasaki, Mateusz Zurowski, Ji Hyun Ko, Sang Soo Cho, Giovanna Pellecchia, Francesca Antonelli, Sylvain Houle, Anthony E Lang, Antonio P Strafella.   

Abstract

Impulse control disorders such as pathological gambling (PG) are a serious and common adverse effect of dopamine (DA) replacement medication in Parkinson's disease (PD). Patients with PG have increased impulsivity and abnormalities in striatal DA, in common with behavioural and substance addictions in the non-PD population. To date, no studies have investigated the role of extrastriatal dopaminergic abnormalities in PD patients with PG. We used the PET radiotracer, [11C] FLB-457, with high-affinity for extrastriatal DA D2/3 receptors. 14 PD patients on DA agonists were imaged while they performed a gambling task involving real monetary reward and a control task. Trait impulsivity was measured with the Barratt Impulsivity Scale (BIS). Seven of the patients had a history of PG that developed subsequent to DA agonist medication. Change in [11C] FLB-457 binding potential (BP) during gambling was reduced in PD with PG patients in the midbrain, where D2/D3 receptors are dominated by autoreceptors. The degree of change in [11C] FLB-457 binding in this region correlated with impulsivity. In the cortex, [11C] FLB-457 BP was significantly greater in the anterior cingulate cortex (ACC) in PD patients with PG during the control task, and binding in this region was also correlated with impulsivity. Our findings provide the first evidence that PD patients with PG have dysfunctional activation of DA autoreceptors in the midbrain and low DA tone in the ACC. Thus, altered striatal and cortical DA homeostasis may incur vulnerability for the development of PG in PD, linked with the impulsive personality trait.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766031      PMCID: PMC3465363          DOI: 10.1016/j.nbd.2012.06.021

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  61 in total

1.  Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain.

Authors:  H Olsson; C Halldin; C G Swahn; L Farde
Journal:  J Cereb Blood Flow Metab       Date:  1999-10       Impact factor: 6.200

2.  Reproducibility of [11 C]FLB 457 binding in extrastriatal regions.

Authors:  Y Sudo; T Suhara; M Inoue; H Ito; K Suzuki; T Saijo; C Halldin; L Farde
Journal:  Nucl Med Commun       Date:  2001-11       Impact factor: 1.690

Review 3.  Topographic organization of ascending dopaminergic projections.

Authors:  J H Fallon
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 4.  Pharmacology of dopamine agonists in the treatment of Parkinson's disease.

Authors:  Peter Jenner
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

5.  6-Hydroxydopamine lesions reduce specific [3H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors.

Authors:  M Morelli; E Carboni; S Devoto; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1987-08-04       Impact factor: 4.432

6.  Impulse control disorders in Parkinson disease: a multicenter case--control study.

Authors:  Valerie Voon; Mandy Sohr; Anthony E Lang; Marc N Potenza; Andrew D Siderowf; Jacqueline Whetteckey; Daniel Weintraub; Glen R Wunderlich; Mark Stacy
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

7.  Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons.

Authors:  L A Chiodo; M J Bannon; A A Grace; R H Roth; B S Bunney
Journal:  Neuroscience       Date:  1984-05       Impact factor: 3.590

Review 8.  The principal features and mechanisms of dopamine modulation in the prefrontal cortex.

Authors:  Jeremy K Seamans; Charles R Yang
Journal:  Prog Neurobiol       Date:  2004-09       Impact factor: 11.685

9.  L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease.

Authors:  Roshan Cools; Roger A Barker; Barbara J Sahakian; Trevor W Robbins
Journal:  Neuropsychologia       Date:  2003       Impact factor: 3.139

10.  Analysis of emission tomographic scan data: limitations imposed by resolution and background.

Authors:  R M Kessler; J R Ellis; M Eden
Journal:  J Comput Assist Tomogr       Date:  1984-06       Impact factor: 1.826

View more
  47 in total

Review 1.  Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.

Authors:  I Aracil-Bolaños; A P Strafella
Journal:  Parkinsonism Relat Disord       Date:  2015-08-12       Impact factor: 4.891

Review 2.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

3.  Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.

Authors:  Daniel O Claassen; Wery P M van den Wildenberg; Madaline B Harrison; Nelleke C van Wouwe; Kristen Kanoff; Joseph S Neimat; Scott A Wylie
Journal:  Pharmacol Biochem Behav       Date:  2014-11-29       Impact factor: 3.533

4.  Molecular imaging of impulse control disorders in Parkinson's disease.

Authors:  Joonas Majuri; Juho Joutsa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-31       Impact factor: 9.236

Review 5.  Imaging impulse control disorders in Parkinson's disease and their relationship to addiction.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  J Neural Transm (Vienna)       Date:  2012-12-12       Impact factor: 3.575

6.  Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice.

Authors:  Patrick S Johnson; Jeffrey S Stein; Rochelle R Smits; Gregory J Madden
Journal:  J Exp Anal Behav       Date:  2013-02-22       Impact factor: 2.468

Review 7.  Imaging insights into basal ganglia function, Parkinson's disease, and dystonia.

Authors:  A Jon Stoessl; Stephane Lehericy; Antonio P Strafella
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

8.  Liking, wanting, and the incentive-sensitization theory of addiction.

Authors:  Kent C Berridge; Terry E Robinson
Journal:  Am Psychol       Date:  2016-11

Review 9.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

10.  Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.

Authors:  Joel T Dunn; Chloe Clark-Papasavas; Paul Marsden; Stacey Baker; Marcel Cleij; Shitij Kapur; Robert Kessler; Robert Howard; Suzanne J Reeves
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-17       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.